Searched over 200M research papers
8 papers analyzed
These studies suggest that 2.5 mg of lisinopril lowers blood pressure, but the exact amount of reduction is not specified.
20 papers analyzed
Lisinopril is a long-acting angiotensin-converting enzyme (ACE) inhibitor commonly used to manage hypertension. It is effective in reducing blood pressure (BP) in various populations, including children, adults, and the elderly .
Several studies have investigated the dose-response relationship of lisinopril in hypertensive patients. A study involving hypertensive children demonstrated that a 2.5 mg dose of lisinopril effectively lowered blood pressure within two weeks, showing a clear dose-response relationship. This indicates that even at lower doses, lisinopril can significantly impact BP reduction.
In a study comparing the efficacy of different antihypertensive medications, lisinopril at a dose of 2.5 mg was part of a combination therapy with amlodipine. This combination was found to be effective in significantly lowering blood pressure in patients with metabolic syndrome. Although the study primarily focused on combination therapy, it highlights the potential of 2.5 mg lisinopril as part of an effective treatment regimen.
Research on the dose-peak effect relationship of lisinopril in adults with essential hypertension showed that a 2.5 mg dose produced a measurable antihypertensive effect, although higher doses (10 mg and 20 mg) were more effective. This suggests that while 2.5 mg of lisinopril can lower blood pressure, the extent of reduction may be less pronounced compared to higher doses.
In summary, 2.5 mg of lisinopril can effectively lower blood pressure, particularly when used as part of a combination therapy or in specific patient populations such as children. However, the degree of BP reduction may be less significant compared to higher doses. For optimal blood pressure management, the dosage may need to be adjusted based on individual patient response and clinical guidelines.
Most relevant research papers on this topic